Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haemophilus influenzae type b conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- Beijing Minhai Biological
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Haemophilus influenzae type b conjugate vaccine (Minhai-HIB) is a prophylactic, conjugated vaccine developed to prevent infections caused by Haemophilus influenzae type b (Hib), a bacterium responsible for severe diseases such as bacterial meningitis, pneumonia, and other invasive infections primarily in children under 5 years of age. The vaccine consists of the capsular polysaccharide from Hib covalently linked to tetanus toxoid, which enhances immunogenicity by inducing a T-cell dependent immune response. Developed and manufactured by Beijing Minhai Biological Technology, it is approved in China for the prevention of Hib infections[1][2][7].
- Brand names
- Minhai-HIB
- Other names
- Haemophilus influenzae type b conjugate vaccine (Minhai Biological)Hib vaccine conjugate (Minhai Biological)
02
Targets
TT (Tetanus toxoid)
Beyond the preview
Go deeper on Haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus influenzae type b conjugate vaccine.